Last reviewed · How we verify
Triptorelin 0.2 mg
At a glance
| Generic name | Triptorelin 0.2 mg |
|---|---|
| Also known as | Decapeptyl 0.2 mg |
| Sponsor | Elisha Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation. (PHASE3)
- Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. (PHASE4)
- Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles (PHASE3)
- Cell-free DNA Analysis of Spent Embryo Culture Media as a Non-invasive Approach for Preimplantation Genetic Diagnosis
- A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) (PHASE2)
- Triggering Oocyte Maturation in Normoresponders Using Double Trigger or HCG Trigger (PHASE2)
- Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration (PHASE4)
- GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triptorelin 0.2 mg CI brief — competitive landscape report
- Triptorelin 0.2 mg updates RSS · CI watch RSS
- Elisha Hospital portfolio CI